ERBB2 and breast carcinoma: Denkert et al. (Denkert et al., 2018) have demonstrated that increased TIL concentration was associated with good response to neoadjuvant chemotherapy in all molecular subtypes of breast cancer and with a survival benefit in HER2-positive and triple-negative breast cancer.